• Keymed Biosciences annual report for year ended Dec. 31, 2025 flagged shift toward dual engine of R&D, commercialization, led by full commercial launch of IL-4Rα antibody Kangyueda.
• Kangyueda secured NRDL listing in Dec. 2025 for three indications, covering atopic dermatitis, chronic rhinosinusitis with nasal polyps, seasonal allergic rhinitis.
• International partnering advanced, with AstraZeneca accelerating global Phase III program for Claudin 18.2 ADC CMG901/AZD0901.
• Pipeline momentum highlighted by Phase I readout for TSLP x IL-13 bispecific CM512, with multiple Phase II studies underway across respiratory, dermatology indications.
• Gilead agreed in March 2026 to acquire partner Ouro, positioning Keymed to receive about USD 250 million upfront, up to USD 70 million milestone tied to CM336/OM336 rights outside Greater China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260429-12132779), on April 29, 2026, and is solely responsible for the information contained therein.